From acquisitions and laboratory expansions to new company launches, industry momentum is being driven by innovation, customisation and global outreach.
Alpha Laboratories joins Diploma in strategic acquisition
Alpha Laboratories, one of the UK and Ireland’s fastest-growing diagnostics providers, has been acquired by FTSE 100-listed Diploma plc.
The acquisition brings Alpha under the umbrella of a decentralised, customer-focused group known for delivering value-added technical solutions across life sciences, seals and controls.
Alpha will maintain its brand identity, operations, and leadership, continuing to serve key markets such as bowel cancer and inflammatory bowel disease screening.
Rob Vint, Alpha’s Managing Director, cited shared values in sustainability, ESG performance and clinical expertise as a foundation for the partnership.
The move enables Alpha to benefit from the commercial strength and compliance standards of a public company while preserving its agility and customer-centric approach.
Coriolis Pharma expands to US with $10m investment in North Carolina
German-based CRDO Coriolis Pharma has announced a $10 million investment in a new state-of-the-art laboratory in Morrisville, North Carolina.
The facility, located at Spark Life Science campus near the renowned Research Triangle Park, is part of Coriolis’ strategic North American expansion and will initially offer services such as particle identification and formulation development.
The 13,000 sq ft site will serve as a regional hub, tightly integrated with Coriolis’ global operations and designed to support future advances in digital and in-silico technologies.
CEO Silvia Steyrer-Gruber highlighted the region’s vibrant biotech ecosystem and infrastructure as decisive factors behind the location choice. The new site will create 50 skilled jobs and is set to open in early 2026.
Logical Biological launches Logical Antigen to accelerate IVD innovation
UK-based Logical Biological has launched a sister company, Logical Antigen, to meet growing global demand for customised antigens and protein purification services within the in vitro diagnostics (IVD) market.
Operating from new lab space at Discovery Park in Kent, UK, Logical Antigen brings together a founding team with more than two decades of protein purification expertise each.
Logical Antigen aims to drastically cut development timelines by offering native and recombinant antigen customisation, as well as advanced plasma and serum engineering.
The company is structured as part of the ‘One Logical’ group and leverages Logical Biological’s commercial infrastructure and industry experience.
The move marks another phase in Logical Biological’s strategic growth, underpinned by strong financial performance and increasing investment in customisation capabilities for IVD manufacturers.
These latest developments highlight the pharmaceutical industry’s strong focus on strategic partnerships, geographic expansion and technical innovation, setting the stage for continued growth and transformation.